Bibliographic Details
| Title: |
Current and Emerging Radiotracers and Technologies for Detection of Advanced Differentiated Thyroid Cancer: A Narrative Review. |
| Authors: |
Pishdad, Reza, Santhanam, Prasanna |
| Source: |
Cancers; Feb2025, Vol. 17 Issue 3, p425, 15p |
| Subject Terms: |
ARGININE, GALLIUM isotopes, THYROID gland tumors, MEDICAL technology, DIAGNOSTIC imaging, IODINE radioisotopes, RADIOPHARMACEUTICALS, SINGLE-photon emission computed tomography, DEOXY sugars, POSITRON emission tomography, POSITRON emission tomography computed tomography, DECISION making in clinical medicine, RADIOISOTOPES, MAGNETIC resonance imaging, DIAGNOSTIC errors, RADIOISOTOPES in medical diagnosis, BONE metastasis, NANOTECHNOLOGY, GLYCINE, PROSTATE-specific membrane antigen, ASPARTIC acid, MOLECULAR diagnosis, NANOPARTICLES |
| Abstract: |
Simple Summary: Differentiated thyroid cancer is a common type of thyroid cancer, but its diagnosis and treatment become challenging in advanced stages, especially when traditional imaging methods are less effective. This review explores innovative imaging agents called radiotracers, which can improve the detection of DTC and provide more precise information about the cancer's behavior. By highlighting the strengths and future potential of these advanced imaging techniques, the authors aim to help researchers and healthcare providers better diagnose and manage thyroid cancer. These advancements could pave the way for personalized treatments and improved outcomes for patients with advanced DTC, while also inspiring further research in this area. Advanced differentiated thyroid cancer (DTC) presents diagnostic challenges, especially in cases refractory to conventional therapies. This review explores emerging radiotracers and imaging technologies designed to enhance diagnostic accuracy and therapeutic decision-making. Iodine-based radiopharmaceuticals, including I-123, I-131, and I-124 PET/CT, remain essential for detecting radioiodine-avid DTC, leveraging sodium-iodide symporter (NIS) expression. However, heterogeneity in NIS functionality often limits their effectiveness. Novel agents like [18F] FSO3 and [18F] TFB show promise in improving molecular imaging specificity. For radioiodine-refractory DTC (RAI-R), 18F-FDG PET/CT remains the cornerstone, aiding in disease localization, therapy monitoring, and prognosis. Emerging modalities, such as 68Ga-DOTA-based agents targeting somatostatin receptors (SSTR) and 68Ga-FAPI for fibroblast activation protein imaging, offer high sensitivity for poorly differentiated lesions and metastatic disease. Additionally, PSMA- and RGD-based imaging provide unique avenues for theranostic applications by targeting tumor neovascularization and integrin expression. The integration of nanotechnology, theranostic principles, and advanced imaging probes continues to evolve, enabling personalized approaches to DTC management. By summarizing these advancements, this review underscores the growing potential of molecular imaging and theranostics in addressing the unmet needs of advanced and refractory DTC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
